tic stem cell transplantation Hemorrhagic cystitis (HC) is a common complication after hematopoietic stem cell transplantation (HSCT), with a reported incidence of 7-70%. 1 In the HSCT setting, it is well known that late-onset HC (LHC) is mainly attributed to viral infection, whereas early-onset HC is mainly due to the toxicity of cyclophosphamide. Adenovirus (AdV) type 11 is the prominent pathogen for LHC in Japan, 2, 3 while BK virus (BKV)-associated LHC is frequently seen all over the world. 4, 5 Several risk factors associated with LHC, including old age, allogeneic HSCT, graft-versus-host-disease (GVHD), and the use of busulfan in a conditioning regimen, have been reported in several studies. 1, 5, 6 However, most of these risks have not been observed consistently. Furthermore, the incidence and risk factors may differ among populations, considering that LHC is mainly caused by viral infections. In this study, we retrospectively analyzed the etiology and risk factors of LHC in Japanese adult HSCT recipients.
Patients and methods

Study population
We analyzed the records of 141 consecutive adult patients (415 years old) who underwent conventional allogeneic HSCT for the first time at the University of Tokyo Hospital between June 1995 and May 2002. The median age was 35.0 years (range 16-59). Patients who received reducedintensity conditioning were not included in the study. In all, 79 and 62 patients received graft from relatives and unrelated donors, respectively. Unrelated HSCT was performed exclusively using bone marrow, whereas 14 relatives donated a peripheral blood stem cell graft. In total, 47 patients received an HLA-mismatched graft. The underlying disease was acute myeloblastic leukemia (AML) in 32, acute lymphoblastic leukemia (ALL) in 36, chronic myelogenous leukemia (CML) in 42, myelodysplastic syndrome (MDS) in 15, non-Hodgkin's lymphoma (NHL) in eight, aplastic anemia (AA) in seven, and adult T-cell leukemia/lymphoma (ATL) in one. Acute leukemia in first remission, CML in first chronic phase, MDS without leukemic transformation, NHL in complete response, and AA were defined as low-risk disease.
Transplantation procedure
The preparative regimen was mainly either cyclophosphamide at 120 mg/kg with busulfan at 16 mg/kg or cyclophosphamide at the same dose with total body irradiation at 1200 cGy. Mesna was administered at 400-800 mg three times a day with hyperhydration to prevent cyclophosphamide-induced HC. Prophylaxis against GVHD consisted of cyclosporine or tacrolimus combined with short-term methotrexate.
As herpes simplex virus prophylaxis, acyclovir was given 1000 mg/day orally or 750 mg/day intravenously from days À7 to 35 after HSCT. Pre-emptive therapy against cytomegalovirus (CMV) was performed by monitoring CMV antigenemia weekly after engraftment.
Definition of LHC and samples for virus detection
To exclude regimen-related HC, only patients who developed macroscopic hematuria or sustained microhematuria for more than 14 days with clinical signs of cystitis de novo at least 10 days after HSCT and who did not have a tendency for generalized bleeding or bacteriuria were considered to have LHC. The severity of LHC was graded according to previously reported criteria; 1 mild: sustained microscopic hematuria, moderate: gross hematuria and dysuria with or without clots, and severe: passage of clots with bladder pain requiring irrigation or the presence of complications including urinary tract obstruction and renal dysfunction requiring surgical intervention or chemical coagulation. Urine samples from all of the 19 patients with LHC were subjected to the following analyses to detect viral infections. Available frozen serum samples from six patients were also analyzed.
Urine viral culture
A volume of 2 ml of urine was centrifuged overnight at 20 000g and the sediment was cocultured with Hep-2 cells for up to 4 weeks. When a cytopathic sign of viral infection was observed, the viral species were identified using monoclonal antibodies against AdV.
PCR of urine samples
After 2 ml of a urine sample was centrifuged at 15 000g for 1 h at 41C, DNA was extracted from the sediment using a GIAmp DNA Blood Mini Kit (QIAGEN, Hilden, Germany). On the other hand, 200 ml of serum sample was directly applied to the kit to extract DNA. Next, 5 mg of purified DNA was subjected to a PCR assay using a GeneAmp Kit and GeneAmp PCR System 9600 (Perkin-Elmer, NJ, USA) with the following primers; AD185S (5-tccagcaacttcatgtccatgg-3) and AD 185A (5-tcgatgacgccgcggt-3) to screen for AdV infection, AD11BKOS (5-aatacaactggtgaggaacacgtaacag-3), AD11-BXUA (5-ccgcatcaaaaaactccatgtcgatatcat-3), AD11BXIS (5-tggaagtttcagatgaagaaagtaaaccga-3), and AD11BTIA (5-caaaggacccgtagcatggtttc-3) for AdV type 11-specific nested PCR, and BKV-1 (5-gcaagtgccaaaactactaat-3) and BKV-2 (5-tgcatgaaggttaagcatgc-3) to detect BKV infection. The size of the final products was confirmed by 3% agarose gel electrophoresis. The sensitivities of the PCR assay to screen AdV infection, Adv type 11-specific PCR, and BKV PCR were 200, 50, and 200 copies/ml, respectively.
Statistical analysis
The cumulative incidence of LHC and the impact of risk factors on LHC were evaluated using Gray's method, considering death without LHC as a competing risk. 7 Possible pretransplant factors analyzed in this study included age, sex, donor, graft source, risk of primary disease, and the use of busulfan in the preparative regimen.
To evaluate the influence of the development of grade II-IV acute GVHD, proportional hazard modeling was used, treating the development of acute GVHD as a timedependent covariate. Factors associated with at least borderline significance (Po0.10) in the univariate analyses were subjected to a multivariate analysis using backward stepwise proportional-hazard modeling. P-values of less than 0.05 were considered statistically significant.
Results
The incidence of LHC
In all, 19 patients developed LHC with a median onset of 51 days (range 11-380) after HSCT, with a 2-year cumulative incidence of LHC of 14.2%. All but one of the patients with LHC were male. Eight, nine, and two patients had severe, moderate, and mild LHC, respectively. The median duration of symptoms was 35 days (range 3-151). While LHC was mainly treated by supportive modalities including hydration and/or blood transfusions, seven patients required bladder irrigation and two received antiviral agents including cidofovir and vidarabine.
Clinical outcome of LHC patients
Nine of the 19 LHC patients died at a median of 57 days (range 29-364) after the onset of LHC. The cause of death was thrombotic microangiopathy in three, acute GVHD in two, invasive aspergillosis in two, and interstitial pneumonitis in two. Two of the nine patients developed AdV pneumonia, which was not the major cause of death. The 3-year actuarial survival rate among LHC patients was only 27%.
Analysis of urine and serum samples
AdV was detected in the urine samples of 10 LHC patients, of whom eight had AdV type 11 (Table 1) . Serum samples were available in six of these eight patients and five of them were also positive for AdV type 11. The outcome of the patients with positive serum AdV DNA was similar to that of the other LHC patients (the median duration of symptoms was 45 days and three died due to unrelated causes). BKV was detected in the urine of 10 LHC patients, but six of them also had AdV type 11 infection.
Risk factors for LHC
Among the possible confounding factors, only the male sex and the development of grade II-IV acute GVHD were identified as significant risk factors for LHC by a univariate analysis (Table 2, Figure 1 ). These two factors were confirmed to be independently significant by proportional hazard modeling, with relative risks of 7.52 (95% CI; 1.00-56.4, P ¼ 0.050) and 4.37 (95% CI; 1.65-11.6, P ¼ 0.0031), respectively.
Late 
Discussion
In this population, the cumulative incidence of LHC was 14.3% and approximately half of the LHC patients had AdV infection. Male sex and the development of acute GVHD were identified as independent risk factors for LHC. While patients who developed LHC showed poor survival, the severe background clinical status, rather than LHC itself, appeared to be responsible for the poor outcome. The incidence of LHC in our series was almost the same as that of Japanese adult HSCT recipients reported by Miyamura et al 2 and
Akiyama et al. 3 In contrast, Kondo et al 8 reported that a lower incidence of LHC in Japanese pediatric HSCT recipients.
The development of grade II-IV acute GVHD was identified as an independent risk factor for LHC. Among the 13 LHC patients who developed acute GVHD, only one did so after the onset of LHC. This patient had received steroid pulse therapy against engraftment syndrome before he developed LHC. The median dose of corticosteroid and the median absolute lymphocyte count at the onset of LHC were 75 mg/day and 264/mm 3 . These findings suggest that immunosuppression due to the development of acute GVHD and/or the use of steroid might be responsible for the development of LHC.
AdV was isolated by means of viral culture and/or PCR in 53% of the urine specimens of LHC patients, and most of the isolates were classified as AdV type 11. The incidence of AdV-associated LHC in our group of patients agreed with that in the previous reports from Japan, but was much higher than that in reports from the West. 4, 5 The relationship between BKV infection and the development of LHC has been reported to be unclear. 4 BKV was frequently detected in the urine of non-LHC patients, whereas AdV was almost exclusively detected in LHC patients in a previous Japanese study. 3 In this study, four of the eight patients with AdV type 11 LHC were coinfected with BKV. However, neither the severity of LHC (three severe and one moderate in both groups) nor the outcome (two died and two are alive in both groups) was different between BKV-positive and -negative groups. We used a qualitative Table 2 Influence of confounding factors on the incidence of late-onset hemorrhagic cystitis after hematopoietic stem cell transplantation Late-onset HC after hematopoietic stem cell transplantation Y Asano et al PCR with a sensitivity of 200 copies/ml to detect BKV. Quantitative PCR may be required to further clarify the impact of BKV infection on LHC. The route of infection in patients with AdV-associated LHC has not been clarified. AdV can be transmitted by the inhalation of aerosolized virus and by the inoculation of virus into conjunctival sacs, but AdV-associated LHC was usually not preceded by symptoms of acute infection of the upper airway or conjunctiva. The fact that most adults have serum antibody to multiple serotypes of AdV also supports the notion that the reactivation of latent AdV infection, rather than acute infection, may be the major etiology of LHC. Interestingly, we identified male sex as a significant risk factor for the development of LHC. Similarly, the incidence of childhood HC is two to three times higher in boys than in girls. 8 Furthermore, AdV type 11 was shown to be the major causative agent in childhood HC, and its incidence is higher in Japan than in the West. 9 Considering all of these findings together, we considered the hypothesis that AdV type 11 may show tropism to a male-specific organ around the urinary tract, and acute infection in childhood may be followed by a latent infection in this organ. Reactivation of the virus in immunocompromised conditions after HSCT, especially in patients with acute GVHD, may cause LHC, and thus lead to a higher incidence in males.
Five of the six AdV-associated LHC patients examined had AdV type 11 viremia as proven by serum PCR. These serum samples were obtained during the episode of LHC. However, the clinical course of these patients was not different from that of the other LHC patients. On the other hand, some previous studies showed that the detection of AdV DNA in serum by PCR predicts the development of a severe or fatal AdV infection. 10, 11 However, the previous study populations were different from ours; they included pediatric patients or recipients of T-cell-depleted hematopoietic stem cell transplantation. Furthermore, most of these studies did not analyze AdV type 11 but type 1, 2, 5, 12, 31, 34, and 35 infections. Therefore, we considered that the impact of AdV viremia may differ among patient populations, the level of immunosuppression, and/or the serotype of AdV.
In conclusion, LHC after HSCT was predominant in males and patients who developed acute GVHD. The detection of AdV type 11 DNA by serum PCR was not associated with severe AdV infection in this population. However, these findings should be validated in other Japanese adult populations.
